PH12014500519B1 - Humanized anti-factor d antibodies and uses thereof - Google Patents

Humanized anti-factor d antibodies and uses thereof

Info

Publication number
PH12014500519B1
PH12014500519B1 PH12014500519A PH12014500519A PH12014500519B1 PH 12014500519 B1 PH12014500519 B1 PH 12014500519B1 PH 12014500519 A PH12014500519 A PH 12014500519A PH 12014500519 A PH12014500519 A PH 12014500519A PH 12014500519 B1 PH12014500519 B1 PH 12014500519B1
Authority
PH
Philippines
Prior art keywords
antibodies
factor
humanized anti
treatment
prophylaxis
Prior art date
Application number
PH12014500519A
Other languages
English (en)
Other versions
PH12014500519A1 (en
Inventor
Arthur J Huang
Robert F Kelley
Henry Lowman
Lookeren Campagne Menno Van
Charles M Winter
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40999836&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12014500519(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PH12014500519A1 publication Critical patent/PH12014500519A1/en
Publication of PH12014500519B1 publication Critical patent/PH12014500519B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH12014500519A 2008-04-28 2014-03-07 Humanized anti-factor d antibodies and uses thereof PH12014500519B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4843108P 2008-04-28 2008-04-28
US4868908P 2008-04-29 2008-04-29
PCT/US2009/041785 WO2009134711A1 (en) 2008-04-28 2009-04-27 Humanized anti-factor d antibodies and uses thereof

Publications (2)

Publication Number Publication Date
PH12014500519A1 PH12014500519A1 (en) 2017-12-11
PH12014500519B1 true PH12014500519B1 (en) 2019-06-28

Family

ID=40999836

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12014500519A PH12014500519B1 (en) 2008-04-28 2014-03-07 Humanized anti-factor d antibodies and uses thereof

Country Status (35)

Country Link
US (7) US8273352B2 (enExample)
EP (3) EP3002295A1 (enExample)
JP (2) JP5636359B2 (enExample)
KR (2) KR20130084330A (enExample)
CN (2) CN102066419B (enExample)
AR (2) AR071510A1 (enExample)
AU (1) AU2009241348C1 (enExample)
BR (1) BRPI0907701A2 (enExample)
CA (2) CA2908470A1 (enExample)
CL (2) CL2009001001A1 (enExample)
CO (1) CO6331346A2 (enExample)
CR (2) CR20170001A (enExample)
CY (1) CY1116982T1 (enExample)
DK (1) DK2283041T3 (enExample)
EC (1) ECSP10010637A (enExample)
ES (1) ES2552817T3 (enExample)
HK (1) HK1245812A1 (enExample)
HR (1) HRP20151259T1 (enExample)
HU (1) HUE026349T2 (enExample)
IL (3) IL208555A (enExample)
MA (1) MA32300B1 (enExample)
MX (2) MX2010011342A (enExample)
MY (2) MY162350A (enExample)
NZ (3) NZ588457A (enExample)
PE (2) PE20091783A1 (enExample)
PH (1) PH12014500519B1 (enExample)
PL (1) PL2283041T3 (enExample)
PT (1) PT2283041E (enExample)
RS (1) RS54405B1 (enExample)
RU (1) RU2488594C2 (enExample)
SG (2) SG10201608305SA (enExample)
SI (1) SI2283041T1 (enExample)
TW (3) TWI558413B (enExample)
WO (1) WO2009134711A1 (enExample)
ZA (1) ZA201301709B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170002684A (ko) 2005-11-04 2017-01-06 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
CN117903302A (zh) 2005-11-30 2024-04-19 Abbvie 公司 抗-Aβ球聚体抗体，其相关产品，生产所述抗体的方法，所述抗体的应用以及使用方法
TWI472535B (zh) * 2006-11-02 2015-02-11 Genentech Inc 人類化之抗-因子ｄ抗體及其用途
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
US20110165648A1 (en) 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
CN104744591B (zh) 2010-04-15 2022-09-27 Abbvie德国有限责任两合公司 β淀粉样蛋白结合蛋白
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
AU2012212047A1 (en) * 2011-02-03 2013-08-22 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
CN103635875B (zh) 2011-03-25 2018-02-16 英特尔公司 用于通过使用由可分区引擎实例化的虚拟核来支持代码块执行的存储器片段
KR101703400B1 (ko) * 2011-11-22 2017-02-06 소프트 머신즈, 인크. 마이크로프로세서 가속 코드 최적화기
CN112575018A (zh) * 2012-09-19 2021-03-30 弗·哈夫曼-拉罗切有限公司 用于防止正亮氨酸错误地掺入蛋白质中的方法和组合物
TW201427989A (zh) 2012-12-18 2014-07-16 Novartis Ag 長效性蛋白質之組合物及方法
EP2970453B1 (en) 2013-03-13 2019-12-04 Prothena Biosciences Limited Tau immunotherapy
KR102083390B1 (ko) 2013-03-15 2020-03-02 인텔 코포레이션 네이티브 분산된 플래그 아키텍처를 이용하여 게스트 중앙 플래그 아키텍처를 에뮬레이션하는 방법
WO2014197885A2 (en) 2013-06-07 2014-12-11 Duke University Inhibitors of complement factor h
CN107318267B (zh) * 2013-08-12 2021-08-17 豪夫迈·罗氏有限公司 用于治疗补体相关的病症的组合物和方法
EP3054965B1 (en) * 2013-10-07 2021-04-14 Massachusetts Eye & Ear Infirmary Anti-factor d antibody for use in preventing or reducing retinal detachment
PE20161440A1 (es) 2014-05-01 2017-01-26 Genentech Inc Variantes del anticuerpo anti-factor d y sus usos
EP3160990A2 (en) 2014-06-25 2017-05-03 Novartis AG Compositions and methods for long acting proteins
EP3160991A2 (en) 2014-06-25 2017-05-03 Novartis AG Compositions and methods for long acting proteins
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
SI3368579T1 (sl) * 2015-10-30 2022-04-29 F.Hoffmann-La Roche Ag Tečajni modificirani fragmenti protitelesa in metode priprave
PL3368578T3 (pl) 2015-10-30 2021-07-26 F. Hoffmann-La Roche Ag Przeciwciała anty-Htra1 i sposoby ich stosowania
TW201730211A (zh) * 2015-10-30 2017-09-01 建南德克公司 抗因子d抗體及結合物
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
EP3368565A1 (en) * 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody formulations
PL3368682T3 (pl) 2015-10-30 2020-05-18 F. Hoffmann-La Roche Ag Sposoby pomiaru aktywności czynnika D i siły działania inhibitorów czynnika D
WO2017091719A1 (en) * 2015-11-24 2017-06-01 Annexon, Inc. Anti-complement factor c1q fab fragments and uses thereof
CA3010056A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
CA3011819A1 (en) 2016-01-20 2017-07-27 Vitrisa Therapeutics, Inc. Compositions and methods for inhibiting factor d
WO2017129064A1 (zh) * 2016-01-28 2017-08-03 成都康弘生物科技有限公司 抗补体因子D的人源化Fab和人源化抗体及其用途
PT3452507T (pt) 2016-05-02 2022-12-20 Prothena Biosciences Ltd Imunoterapia anti-tau
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
EP3580241A4 (en) 2017-02-10 2021-01-06 The Trustees Of The University Of Pennsylvania ANTI-FACTOR D ANTIBODIES AND USES OF THESE LATEST
CN106905431B (zh) * 2017-04-10 2020-01-17 旭华（上海）生物研发中心有限公司 抗人补体d因子的单克隆抗体及其用途
US11584790B2 (en) 2017-04-14 2023-02-21 Kodiak Sciences Inc. Complement factor D antagonist antibodies and conjugates thereof
CN110881274B (zh) 2017-05-02 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
US12172106B2 (en) 2018-08-09 2024-12-24 Regeneron Pharmaceuticals, Inc. Methods for assessing binding affinity of an antibody variant to the neonatal Fc receptor
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
US12486322B2 (en) 2021-12-13 2025-12-02 Annexon, Inc. Anti-complement factor C1q antibodies with single binding arms and uses thereof
WO2025208782A1 (en) * 2024-04-02 2025-10-09 Linno (Hangzhou) Pharmaceuticals Inc. Cfd-binding antibody fragments and uses thereof

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4946783A (en) 1987-01-30 1990-08-07 President And Fellows Of Harvard College Periplasmic protease mutants of Escherichia coli
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
US5169770A (en) 1987-12-21 1992-12-08 The University Of Toledo Agrobacterium mediated transformation of germinating plant seeds
US5256642A (en) 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
IL94611A (en) 1989-06-05 1994-12-29 Organogenesis Inc Medium for cell cultures containing insulin or growth factor similar to insulin, transferrin or iron ion, triiodothyronine or thyroxine and method of use
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
DE122004000008I1 (de) * 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5456909A (en) 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
ZA936128B (en) 1992-08-21 1995-02-20 Genentech Inc Method for treating a LFA-1 mediated disorder
US5861156A (en) 1993-01-08 1999-01-19 Creative Biomolecules Methods of delivering agents to target cells
US5856300A (en) 1994-05-12 1999-01-05 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5679546A (en) 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
US5627264A (en) 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
ES2236706T3 (es) 1994-03-23 2005-07-16 Alexion Pharmaceuticals, Inc. Procedimiento para reducir las disfunciones de los sistemas inmunitario y hemostatico durante la circulacion extracorporal.
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5679345A (en) 1994-06-02 1997-10-21 The Johns Hopkins University Method for preventing complement-dependent rejection of organ or tissue transplants
WO2001004311A1 (en) 1999-07-07 2001-01-18 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US5679564A (en) 1994-10-05 1997-10-21 Antex Biologics, Inc. Methods for producing enhanced antigenic campylobacter bacteria and vaccines
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6027888A (en) 1996-04-05 2000-02-22 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide-bond containing eukaryotic proteins in bacterial cells
US20050197285A1 (en) 1997-03-07 2005-09-08 Rosen Craig A. Human secreted proteins
US6472520B2 (en) 1997-03-21 2002-10-29 The Trustees Of Columbia University In The City Of New York Rat PEG-3 promoter
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
US6410708B1 (en) 1997-11-21 2002-06-25 Genentech, Inc. Nucleic acids encoding A-33 related antigen polypeptides
NZ503033A (en) 1997-08-26 2003-01-31 Gliatech Inc Inhibition of complement activation using anti-properdin agents
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
EP2014677A1 (en) 1997-11-21 2009-01-14 Genentech, Inc. A-33 related antigens and their pharmacological uses
US7282565B2 (en) 1998-03-20 2007-10-16 Genentech, Inc. PRO362 polypeptides
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
AU2577799A (en) 1998-02-09 1999-08-23 Human Genome Sciences, Inc. 45 human secreted proteins
US7112327B2 (en) 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
US6956107B2 (en) * 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
PT1054693E (pt) * 1998-02-20 2009-01-22 Genentech Inc Inibidores da activação do complemento
PT1490386E (pt) 1998-03-10 2008-11-24 Genentech Inc Novos polipéptidos e ácidos nucleicos que os codificam
EP1108019A2 (en) 1998-08-27 2001-06-20 Incyte Pharmaceuticals, Inc. Protein transport-associated molecules
MXPA01006057A (es) 1998-12-16 2003-09-10 Genentech Inc Polipeptidos secretados y transmembranales y acidos nucleicos que los codifican.
AU768230B2 (en) 1998-12-22 2003-12-04 Genentech Inc. Methods and compositions for inhibiting neoplastic cell growth
KR101155191B1 (ko) 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
JP2004516227A (ja) 1999-03-08 2004-06-03 ジェネンテック・インコーポレーテッド 免疫関連疾患を治療するための組成物と方法
EE05497B1 (et) 1999-03-11 2011-12-15 Rmf Dictagene S.A. Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
US6642353B1 (en) 1999-03-17 2003-11-04 Chugai Seiyaku Kabushiki Kaisha Peptide ligands for the erythropoietin receptor
CA2388777A1 (en) 1999-11-19 2001-05-25 Human Genome Sciences, Inc. 18 human secreted proteins
EP1250426A2 (en) 1999-12-01 2002-10-23 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding same
US6821775B1 (en) 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
ES2329010T3 (es) 2000-03-23 2009-11-20 Genentech, Inc. Inhibidores anti-c2/c2a de la activacion del complemento.
DK2026073T3 (en) 2000-04-29 2016-07-25 Univ Iowa Res Found Diagnosis and treatment of macular degeneration-related disorders
EP1309620A2 (en) 2000-06-23 2003-05-14 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
JP2004516013A (ja) 2000-07-20 2004-06-03 ジェネンテック・インコーポレーテッド 血管形成に関連する障害を診断及び治療するための組成物と方法
CA2424379C (en) 2000-10-10 2013-10-01 Tanox, Inc. Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
TR200602095T2 (tr) 2000-10-13 2007-02-21 Biogen Idec Ma Inc. Hümanize Anti-LT-Beta-R antikorları
US20040077575A1 (en) 2002-01-11 2004-04-22 Giordano Giovan Giacomo Inhibition of pathological angiogenesis in vivo
BRPI0211953B8 (pt) 2001-08-17 2021-05-25 Genentech Inc anticorpo monoclonal ou fragmento de ligação a antígeno que se liga a c5 e c5a sem a prevenção da formação de c5b, linhagem celular, composição farmacêutica, bem como método in vitro para inibir a atividade de c5a e método de diagnóstico in vitro
TWI323265B (en) * 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
WO2004022594A2 (en) 2002-09-06 2004-03-18 Cytos Biotechnology Ag Immune modulatory compounds and methods
US7816497B2 (en) 2002-10-30 2010-10-19 University Of Kentucky Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
RU2232991C1 (ru) 2003-04-09 2004-07-20 Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Способ определения функциональной активности фактора d комплемента человека
US7709610B2 (en) * 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
WO2005014849A2 (en) 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
WO2005025509A2 (en) 2003-09-11 2005-03-24 Board Of Regents, The University Of Texas System Methods and materials for treating autoimmune diseases and conditions
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US7127355B2 (en) 2004-03-05 2006-10-24 Perlegen Sciences, Inc. Methods for genetic analysis
US7794713B2 (en) * 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
CN101142321B (zh) 2004-11-18 2012-06-06 耶鲁大学 治疗眼病的方法和组合物
WO2006071856A2 (en) 2004-12-23 2006-07-06 Glycofi, Inc. Immunoglobulins comprising predominantly a man5glcnac2 glycoform
EP2377951A1 (en) 2005-02-14 2011-10-19 University of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
JP5620058B2 (ja) 2005-06-08 2014-11-05 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 染色体１０ｑ２６上の加齢性黄斑変性症（ＡＲＭ）に対する感受性遺伝子
DK1951279T3 (en) 2005-10-08 2017-07-31 Apellis Pharmaceuticals Inc COMPSTATIN AND ANALOGUES THEREOF FOR EYE DISEASES
KR20170002684A (ko) 2005-11-04 2017-01-06 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
TWI472535B (zh) * 2006-11-02 2015-02-11 Genentech Inc 人類化之抗-因子ｄ抗體及其用途
JP2010526555A (ja) 2007-05-11 2010-08-05 タフツ・メディカル・センター 加齢関連黄斑変性と関係するポリヌクレオチド及び患者のリスクを評価する方法
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
AU2009251499B2 (en) 2008-04-18 2015-07-16 The General Hospital Corporation Polymorphisms associated with age-related macular degeneration and methods for evaluating patient risk
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
SI2540843T1 (sl) 2008-11-05 2014-10-30 Genentech, Inc. Genetski polimorfizmi in starostna degeneracija makule
WO2010075519A2 (en) 2008-12-23 2010-07-01 Massachusetts Eye & Ear Infirmary Allelic variants associated with advanced age-related macular degeneration
WO2010085542A2 (en) 2009-01-23 2010-07-29 Novartis Ag Biomarkers related to age-related macular degeneration (amd)
US20110165648A1 (en) * 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
JP5651527B2 (ja) * 2011-05-02 2015-01-14 沖電気工業株式会社 無線端末装置、無線通信システム、プログラムおよび無線通信方法

Also Published As

Publication number Publication date
AU2009241348C1 (en) 2013-03-28
MY172433A (en) 2019-11-25
NZ621103A (en) 2015-10-30
HK1193111A1 (zh) 2014-09-12
US8273352B2 (en) 2012-09-25
CA2720853A1 (en) 2009-11-05
US20140065137A1 (en) 2014-03-06
EP2283041B1 (en) 2015-09-02
ZA201301709B (en) 2023-01-25
EP2283041A1 (en) 2011-02-16
BRPI0907701A2 (pt) 2019-12-10
JP2013231045A (ja) 2013-11-14
HK1147503A1 (en) 2011-08-12
PE20140806A1 (es) 2014-07-17
CA2720853C (en) 2015-12-29
AU2009241348B2 (en) 2012-11-15
IL266039A (en) 2019-06-30
AR086272A2 (es) 2013-12-04
US20120328613A1 (en) 2012-12-27
RS54405B1 (sr) 2016-04-28
CL2018000537A1 (es) 2018-07-20
PE20091783A1 (es) 2009-12-04
MX2018013087A (es) 2020-09-02
WO2009134711A8 (en) 2010-10-21
US8614306B2 (en) 2013-12-24
JP5636359B2 (ja) 2014-12-03
SG10201608305SA (en) 2016-11-29
MY162350A (en) 2017-06-15
JP5931008B2 (ja) 2016-06-08
CR11817A (es) 2011-01-13
PT2283041E (pt) 2015-11-24
CR20170001A (es) 2017-08-10
EP3002295A1 (en) 2016-04-06
RU2010148423A (ru) 2012-06-10
TW200944234A (en) 2009-11-01
MX2010011342A (es) 2010-12-06
JP2011521623A (ja) 2011-07-28
KR20110004451A (ko) 2011-01-13
WO2009134711A1 (en) 2009-11-05
US20190185579A1 (en) 2019-06-20
NZ603492A (en) 2014-05-30
SI2283041T1 (sl) 2015-12-31
KR20130084330A (ko) 2013-07-24
SG189756A1 (en) 2013-05-31
CY1116982T1 (el) 2017-04-05
CN103724433B (zh) 2015-11-18
CN102066419A (zh) 2011-05-18
TW201819418A (zh) 2018-06-01
HUE026349T2 (en) 2016-06-28
AU2009241348A1 (en) 2009-11-05
HRP20151259T1 (hr) 2015-12-18
TWI558413B (zh) 2016-11-21
PL2283041T3 (pl) 2016-01-29
CL2009001001A1 (es) 2010-05-14
NZ588457A (en) 2012-12-21
AR071510A1 (es) 2010-06-23
US9676868B2 (en) 2017-06-13
PH12014500519A1 (en) 2017-12-11
IL208555A (en) 2017-09-28
HK1245812A1 (en) 2018-08-31
CN102066419B (zh) 2014-07-02
KR101322027B1 (ko) 2013-10-30
IL253014A0 (en) 2017-08-31
US20160145349A1 (en) 2016-05-26
CO6331346A2 (es) 2011-10-20
ES2552817T3 (es) 2015-12-02
US20180100024A1 (en) 2018-04-12
US20090269338A1 (en) 2009-10-29
CA2908470A1 (en) 2009-11-05
CN103724433A (zh) 2014-04-16
TW201437230A (zh) 2014-10-01
IL208555A0 (en) 2010-12-30
RU2488594C2 (ru) 2013-07-27
EP3235829A1 (en) 2017-10-25
US20140212433A1 (en) 2014-07-31
DK2283041T3 (da) 2015-12-07
ECSP10010637A (es) 2010-12-30
MA32300B1 (fr) 2011-05-02
TWI616456B (zh) 2018-03-01
EP3235829B1 (en) 2019-05-22

Similar Documents

Publication Publication Date Title
PH12014500519B1 (en) Humanized anti-factor d antibodies and uses thereof
PH12015501763A1 (en) Humanized anti-factor d antibodies and uses thereof
PH12016502015A1 (en) Anti-factor d antibody variants and uses thereof
EA201001639A1 (ru) Композиции и способы их получения и применения
IN2012DN02737A (enExample)
NZ761188A (en) Antibody molecules to tim-3 and uses thereof
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
MX364200B (es) Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
PH12013501877A1 (en) Nutritional compositions including branched chain fatty acids and methods of using same
NZ630536A (en) Therapeutic agent or prophylactic agent for dementia
WO2015058861A8 (en) Bispecific constructs and their use in the treatment of various diseases
PH12020550598A1 (en) Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells
MX2020010375A (es) Nuevos derivados de ester fosforamidato 3'-desoxiadenosina de 2' y/o 5' aminoacido como compuestos anti-cancer.
MY150931A (en) Substituted oxazolidinones and their use
MX2013001267A (es) ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
BR112012022255A2 (pt) composição farmaceuticaestabilizada
ZA200908583B (en) Substituted (oxazolidinon-5-yl-methyl)-2-thiophene-carboxamides and use thereof in the field of blood coagulation
HK1202868A1 (en) Carboxamide-substituted heteroaryl-pyrazoles and the use thereof
AR114997A2 (es) Anticuerpos anti-factor d humanizados y sus usos
CY1117058T1 (el) Ανθρωποποιημενα αντισωματα αντι-παραγοντα d
WO2012158639A3 (en) Recombinant fusion proteins and methods for use thereof for treatment or prevention of papillomavirus infection
TH112172A (th) แอนติบอดีต้านแฟคเตอร์ d ที่ถูกทำให้เป็นของมนุษย์ และการใช้ของสิ่งนั้น
TN2010000463A1 (en) Compositions and methods for preparing and using same
HK1196706A (en) Rna engineered t cells for the treatment of cancer